BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

C-CAMP announces 2nd edition of Indo Israel innovation bridge in health sector

23 February 2022 | News

The Bridge 2.0 will provide for a strong collaborative platform between Indian and Israeli innovation ecosystems



Bengaluru-based Centre for Cellular and Molecular Platforms or C-CAMP has announced the second edition of its 2021-launched Indo-Israel Innovation Bridge with Bengaluru Consulate General of Israel. The kick-off was done by Naor Gilon, His Excellency, Ambassador of Israel to India, and Dr Taslimarif Saiyed, C-CAMP CEO & Director in the presence of Jonathan Zadka, Consul General (CG) of Israel to South India, Bengaluru.

The Indo Israel Innovation Bridge Edition II aims to take the current, largely exploratory C-CAMP- CG, Israel partnership a notch higher by creating synergistic ecosystem-to-ecosystem tie-ups specifically in the agriculture and medtech sectors, a strong suit of both C-CAMP and the Israeli innovation Ecosystem.

The Bridge 2.0 will provide for a strong collaborative platform between Indian and Israeli innovation ecosystems especially in the medtech sector.

A prominent hurdle in such partnerships is often the internationally variable regulatory pathways and clearance systems. By this agreement, C-CAMP will bring agency to this potential hurdle through its deep ecosystem networks. This apart networking opportunities, incubation access to C-CAMP’s high-end technology platforms, stakeholder connects and a rich, cross-disciplinary academic environment are on offer for technology validation and scale up needs of interested Israeli parties.

The success of Phase I in which 38 Indian cos and 11 Israeli counterparts evinced interest followed by this current call for Phase II of the Indo-Israel Innovation Bridge demonstrate the potential nation-wide impact of such micro-level, domain-specific Indo-Israel collaborations in context of the close alliance between Govt of India and the State of Israel.